{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:13:16Z","timestamp":1790583196599,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K08HL144820"],"award-info":[{"award-number":["1K08HL144820"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL133184"],"award-info":[{"award-number":["R01HL133184"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["5R01HL142777"],"award-info":[{"award-number":["5R01HL142777"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01 HL142663"],"award-info":[{"award-number":["1R01 HL142663"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL142589"],"award-info":[{"award-number":["1R01HL142589"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P30 AG024827"],"award-info":[{"award-number":["P30 AG024827"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 (2019-nCoV) is the pathogenic coronavirus responsible for the global pandemic of COVID-19 disease. The Spike (S) protein of SARS-CoV-2 attaches to host lung epithelial cells through the cell surface receptor ACE2, a process dependent on host proteases including TMPRSS2. Here, we identify small molecules that reduce surface expression of TMPRSS2 using a library of 2,560 FDA-approved or current clinical trial compounds. We identify homoharringtonine and halofuginone as the most attractive agents, reducing endogenous TMPRSS2 expression at sub-micromolar concentrations. These effects appear to be mediated by a drug-induced alteration in TMPRSS2 protein stability. We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). Finally, cells exposed to homoharringtonine and halofuginone, at concentrations of drug known to be achievable in human plasma, demonstrate marked resistance to SARS-CoV-2 infection in both live and pseudoviral in vitro models. Given the safety and pharmacokinetic data already available for the compounds identified in our screen, these results should help expedite the rational design of human clinical trials designed to combat active COVID-19 infection.<\/jats:p>","DOI":"10.1038\/s41467-021-24156-y","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T06:06:11Z","timestamp":1624428371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3467-2871","authenticated-orcid":false,"given":"Yanwen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-0844","authenticated-orcid":false,"given":"Travis B.","family":"Lear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2070-0883","authenticated-orcid":false,"given":"John W.","family":"Evankovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-0898","authenticated-orcid":false,"given":"Mads B.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2108-2696","authenticated-orcid":false,"given":"Bo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-9641","authenticated-orcid":false,"given":"Irene","family":"Alfaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Kennerdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Salminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Camarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina C.","family":"Lockwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhan","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Myerburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"McDyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-7514","authenticated-orcid":false,"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0726-3546","authenticated-orcid":false,"given":"Toren","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2695-5107","authenticated-orcid":false,"given":"Bill B.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"24156_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/resp.13196","volume":"23","author":"Y Yin","year":"2018","unstructured":"Yin, Y. & Wunderink, R. G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 23, 130\u2013137 (2018).","journal-title":"Respirology"},{"key":"24156_CR2","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1128\/JVI.02232-10","volume":"85","author":"I Glowacka","year":"2011","unstructured":"Glowacka, I. et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 85, 4122\u20134134 (2011).","journal-title":"J. Virol."},{"key":"24156_CR3","doi-asserted-by":"crossref","unstructured":"Iwata-Yoshikawa N., et al. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J. Virol. 93, e01815-18 (2019).","DOI":"10.1128\/JVI.01815-18"},{"key":"24156_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.tim.2004.08.008","volume":"12","author":"H Hofmann","year":"2004","unstructured":"Hofmann, H. & Pohlmann, S. Cellular entry of the SARS coronavirus. Trends Microbiol. 12, 466\u2013472 (2004).","journal-title":"Trends Microbiol."},{"key":"24156_CR5","doi-asserted-by":"publisher","first-page":"14614","DOI":"10.1128\/JVI.79.23.14614-14621.2005","volume":"79","author":"HP Jia","year":"2005","unstructured":"Jia, H. P. et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J. Virol. 79, 14614\u201314621 (2005).","journal-title":"J. Virol."},{"key":"24156_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875\u2013879 (2005).","journal-title":"Nat. Med."},{"key":"24156_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","volume":"105","author":"MA Tortorici","year":"2019","unstructured":"Tortorici, M. A. & Veesler, D. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93\u2013116 (2019).","journal-title":"Adv. Virus Res."},{"key":"24156_CR8","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1073\/pnas.0505577102","volume":"102","author":"G Simmons","year":"2005","unstructured":"Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl Acad. Sci. USA 102, 11876\u201311881 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"24156_CR9","doi-asserted-by":"crossref","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"24156_CR10","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"24156_CR11","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727\u201311734 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"24156_CR12","doi-asserted-by":"publisher","first-page":"101212","DOI":"10.1016\/j.isci.2020.101212","volume":"23","author":"JA Jaimes","year":"2020","unstructured":"Jaimes, J. A., Millet, J. K. & Whittaker, G. R. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1\/S2 site. iScience 23, 101212 (2020).","journal-title":"iScience"},{"key":"24156_CR13","doi-asserted-by":"publisher","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","volume":"176","author":"B Coutard","year":"2020","unstructured":"Coutard, B. et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 176, 104742 (2020).","journal-title":"Antivir. Res."},{"key":"24156_CR14","doi-asserted-by":"crossref","unstructured":"Anand, P., Puranik, A., Aravamudan, M., Venkatakrishnan, A. J. & Soundararajan, V. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. Elife 9, e58603 (2020).","DOI":"10.7554\/eLife.58603"},{"key":"24156_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112\u2013116 (2005).","journal-title":"Nature"},{"key":"24156_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1128\/MCB.26.3.965-975.2006","volume":"26","author":"TS Kim","year":"2006","unstructured":"Kim, T. S., Heinlein, C., Hackman, R. C. & Nelson, P. S. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol. Cell Biol. 26, 965\u2013975 (2006).","journal-title":"Mol. Cell Biol."},{"key":"24156_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2017.07.016","volume":"142","author":"LW Shen","year":"2017","unstructured":"Shen, L. W., Mao, H. J., Wu, Y. L., Tanaka, Y. & Zhang, W. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections. Biochimie 142, 1\u201310 (2017).","journal-title":"Biochimie"},{"key":"24156_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/2472555219880475","volume":"25","author":"M Soave","year":"2020","unstructured":"Soave, M., Kellam, B., Woolard, J., Briddon, S. J. & Hill, S. J. NanoBiT complementation to monitor agonist-induced adenosine A1 receptor internalization. SLAS Discov. 25, 186\u2013194 (2020).","journal-title":"SLAS Discov."},{"key":"24156_CR19","doi-asserted-by":"publisher","first-page":"e0171681","DOI":"10.1371\/journal.pone.0171681","volume":"12","author":"S Omar","year":"2017","unstructured":"Omar, S. et al. Respiratory virus infection up-regulates TRPV1, TRPA1 and ASICS3 receptors on airway cells. PLoS One 12, e0171681 (2017).","journal-title":"PLoS One"},{"key":"24156_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1172\/JCI118067","volume":"96","author":"MC Subauste","year":"1995","unstructured":"Subauste, M. C., Jacoby, D. B., Richards, S. M. & Proud, D. Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J. Clin. Investig. 96, 549\u2013557 (1995).","journal-title":"J. Clin. Investig."},{"key":"24156_CR21","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1128\/AAC.01043-16","volume":"60","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto, M. et al. Identification of Nafamostat as a potent inhibitor of Middle East respiratory syndrome Coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob. Agents Chemother. 60, 6532\u20136539 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24156_CR22","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1007\/s00018-004-4222-9","volume":"61","author":"J Cinatl Jr.","year":"2004","unstructured":"Cinatl, J. Jr. et al. Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus. Cell Mol. Life Sci. 61, 2100\u20132112 (2004).","journal-title":"Cell Mol. Life Sci."},{"key":"24156_CR23","doi-asserted-by":"publisher","first-page":"eaao4966","DOI":"10.1126\/sciadv.aao4966","volume":"3","author":"J Zhou","year":"2017","unstructured":"Zhou, J. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci. Adv. 3, eaao4966 (2017).","journal-title":"Sci. Adv."},{"key":"24156_CR24","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-13-1283","volume":"20","author":"V Gandhi","year":"2014","unstructured":"Gandhi, V., Plunkett, W. & Cortes, J. E. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin. Cancer Res. 20, 1735\u20131740 (2014).","journal-title":"Clin. Cancer Res."},{"key":"24156_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-8722-7-2","volume":"7","author":"S L\u00fc","year":"2014","unstructured":"L\u00fc, S. & Wang, J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J. Hematol. Oncol. 7, 2 (2014).","journal-title":"J. Hematol. Oncol."},{"key":"24156_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1083-8791(03)00151-4","volume":"9","author":"M Pines","year":"2003","unstructured":"Pines, M., Snyder, D., Yarkoni, S. & Nagler, A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol. Blood Marrow Transpl. 9, 417\u2013425 (2003).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"24156_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/molecules20010573","volume":"20","author":"M Pines","year":"2015","unstructured":"Pines, M. & Spector, I. Halofuginone\u2014the multifaceted molecule. Molecules 20, 573\u2013594 (2015).","journal-title":"Molecules"},{"key":"24156_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425\u2013479 (1998).","journal-title":"Annu. Rev. Biochem."},{"key":"24156_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nchembio.790","volume":"8","author":"TL Keller","year":"2012","unstructured":"Keller, T. L. et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat. Chem. Biol. 8, 311\u2013317 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"24156_CR30","doi-asserted-by":"publisher","first-page":"e53785","DOI":"10.1371\/journal.pone.0053785","volume":"8","author":"AA Morgan","year":"2013","unstructured":"Morgan, A. A. & Rubenstein, E. Proline: the distribution, frequency, positioning, and common functional roles of proline and polyproline sequences in the human proteome. PLoS One 8, e53785 (2013).","journal-title":"PLoS One"},{"key":"24156_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).","journal-title":"Nat. Commun."},{"key":"24156_CR32","doi-asserted-by":"crossref","unstructured":"Walls A. C., et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292.e6 (2020).","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"24156_CR33","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1128\/JVI.00094-12","volume":"86","author":"M Kawase","year":"2012","unstructured":"Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F. & Matsuyama, S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J. Virol. 86, 6537\u20136545 (2012).","journal-title":"J. Virol."},{"key":"24156_CR34","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1165\/rcmb.2009-0348OC","volume":"43","author":"MM Myerburg","year":"2010","unstructured":"Myerburg, M. M., Harvey, P. R., Heidrich, E. M., Pilewski, J. M. & Butterworth, M. B. Acute regulation of the epithelial sodium channel in airway epithelia by proteases and trafficking. Am. J. Respir. Cell Mol. Biol. 43, 712\u2013719 (2010).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"24156_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20444-8","volume":"8","author":"AT Lennox","year":"2018","unstructured":"Lennox, A. T. et al. ATP12A promotes mucus dysfunction during Type 2 airway inflammation. Sci. Rep. 8, 2109 (2018).","journal-title":"Sci. Rep."},{"key":"24156_CR36","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1074\/jbc.M508381200","volume":"281","author":"IC Huang","year":"2006","unstructured":"Huang, I. C. et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J. Biol. Chem. 281, 3198\u20133203 (2006).","journal-title":"J. Biol. Chem."},{"key":"24156_CR37","doi-asserted-by":"crossref","unstructured":"Sivaraman, H., Er, S. Y., Choong, Y. K., Gavor, E. & Sivaraman, J. Structural basis of the SARS-CoV-2\/SARS-CoV receptor binding and small-molecule blockers as potential therapeutics. Annu. Rev. Pharmacol. Toxicol. 61, 465\u2013493 (2020).","DOI":"10.1146\/annurev-pharmtox-061220-093932"},{"key":"24156_CR38","doi-asserted-by":"crossref","unstructured":"Andersen, P. I. et al. Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine. Viruses 11, 964 (2019).","DOI":"10.3390\/v11100964"},{"key":"24156_CR39","doi-asserted-by":"crossref","unstructured":"Dong, H. J. et al. The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo. Viruses 10, 601 (2018).","DOI":"10.3390\/v10110601"},{"key":"24156_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.antiviral.2018.11.017","volume":"161","author":"J Hwang","year":"2019","unstructured":"Hwang, J., Jiang, A. & Fikrig, E. A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses. Antivir. Res. 161, 163\u2013168 (2019).","journal-title":"Antivir. Res."},{"key":"24156_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","volume":"19","author":"F Alvandi","year":"2014","unstructured":"Alvandi, F. et al. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist 19, 94\u201399 (2014).","journal-title":"Oncologist"},{"key":"24156_CR42","doi-asserted-by":"publisher","first-page":"40318","DOI":"10.18632\/oncotarget.16956","volume":"8","author":"J Chen","year":"2017","unstructured":"Chen, J. et al. Homoharringtonine targets Smad3 and TGF-\u03b2 pathway to inhibit the proliferation of acute myeloid leukemia cells. Oncotarget 8, 40318\u201340326 (2017).","journal-title":"Oncotarget"},{"key":"24156_CR43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12906-018-2233-6","volume":"18","author":"Q Sun","year":"2018","unstructured":"Sun, Q. et al. Homoharringtonine regulates the alternative splicing of Bcl-x and caspase 9 through a protein phosphatase 1-dependent mechanism. BMC Complement. Alter. Med. 18, 164 (2018).","journal-title":"BMC Complement. Alter. Med."},{"key":"24156_CR44","first-page":"113","volume":"43","author":"S Li","year":"2020","unstructured":"Li, S. et al. Homoharringtonine promotes BCR\u2011ABL degradation through the p62\u2011mediated autophagy pathway. Oncol. Rep. 43, 113\u2013120 (2020).","journal-title":"Oncol. Rep."},{"key":"24156_CR45","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"K-T Choy","year":"2020","unstructured":"Choy, K.-T. et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir. Res. 178, 104786\u2013104786 (2020).","journal-title":"Antivir. Res."},{"key":"24156_CR46","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1128\/JVI.00676-08","volume":"82","author":"Y Shirogane","year":"2008","unstructured":"Shirogane, Y. et al. Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J. Virol. 82, 8942\u20138946 (2008).","journal-title":"J. Virol."},{"key":"24156_CR47","doi-asserted-by":"publisher","first-page":"101485","DOI":"10.1016\/j.redox.2020.101485","volume":"32","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. A small molecule NRF2 activator BC-1901S ameliorates inflammation through DCAF1\/NRF2 axis. Redox Biol. 32, 101485\u2013101485 (2020).","journal-title":"Redox Biol."},{"key":"24156_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-14-22","volume":"14","author":"T Nakagawa","year":"2013","unstructured":"Nakagawa, T., Mondal, K. & Swanson, P. C. VprBP (DCAF1): a promiscuous substrate recognition subunit that incorporates into both RING-family CRL4 and HECT-family EDD\/UBR5 E3 ubiquitin ligases. BMC Mol. Biol. 14, 22 (2013).","journal-title":"BMC Mol. Biol."},{"key":"24156_CR49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","volume":"140","author":"W Li","year":"2010","unstructured":"Li, W. et al. Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140, 477\u2013490 (2010).","journal-title":"Cell"},{"key":"24156_CR50","doi-asserted-by":"publisher","first-page":"930","DOI":"10.4049\/jimmunol.1800054","volume":"201","author":"NM Schabla","year":"2018","unstructured":"Schabla, N. M., Perry, G. A., Palmer, V. L. & Swanson, P. C. VprBP (DCAF1) regulates RAG1 expression independently of Dicer by mediating RAG1 degradation. J. Immunol. 201, 930\u2013939 (2018).","journal-title":"J. Immunol."},{"key":"24156_CR51","doi-asserted-by":"crossref","unstructured":"Chang, H. et al. Distinct MCM10 proteasomal degradation profiles by primate lentiviruses Vpr proteins. Viruses 12, 98 (2020).","DOI":"10.3390\/v12010098"},{"key":"24156_CR52","doi-asserted-by":"publisher","first-page":"37333","DOI":"10.1074\/jbc.M110.133181","volume":"285","author":"J Ahn","year":"2010","unstructured":"Ahn, J. et al. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J. Biol. Chem. 285, 37333\u201337341 (2010).","journal-title":"J. Biol. Chem."},{"key":"24156_CR53","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1128\/MCB.00232-08","volume":"28","author":"CM McCall","year":"2008","unstructured":"McCall, C. M. et al. Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. Mol. Cell Biol. 28, 5621\u20135633 (2008).","journal-title":"Mol. Cell Biol."},{"key":"24156_CR54","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1172\/JCI136466","volume":"130","author":"Z Guo","year":"2020","unstructured":"Guo, Z. et al. DCAF1 regulates Treg senescence via the ROS axis during immunological aging. J. Clin. Investig. 130, 5893\u20135908 (2020).","journal-title":"J. Clin. Investig."},{"key":"24156_CR55","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.molcel.2012.09.004","volume":"48","author":"JiM Lee","year":"2012","unstructured":"Lee, Ji. M. et al. EZH2 generates a Methyl Degron that is recognized by the DCAF1\/DDB1\/CUL4 E3 ubiquitin ligase complex. Mol. Cell 48, 572\u2013586 (2012).","journal-title":"Mol. Cell"},{"key":"24156_CR56","doi-asserted-by":"publisher","first-page":"8683","DOI":"10.1128\/JVI.00797-10","volume":"84","author":"X Sun","year":"2010","unstructured":"Sun, X., Tse, L. V., Ferguson, A. D. & Whittaker, G. R. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus. J. Virol. 84, 8683\u20138690 (2010).","journal-title":"J. Virol."},{"key":"24156_CR57","doi-asserted-by":"crossref","unstructured":"Izaguirre, G. The proteolytic regulation of virus cell entry by Furin and other proprotein convertases. Viruses 11, 837 (2019).","DOI":"10.3390\/v11090837"},{"key":"24156_CR58","doi-asserted-by":"crossref","unstructured":"Cheng, J. et al. The S2 subunit of QX-type infectious bronchitis Coronavirus spike protein is an essential determinant of neurotropism. Viruses 11, 972 (2019).","DOI":"10.3390\/v11100972"},{"key":"24156_CR59","first-page":"4180","volume":"59","author":"B Lin","year":"1999","unstructured":"Lin, B. et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180\u20134184 (1999).","journal-title":"Cancer Res."},{"key":"24156_CR60","doi-asserted-by":"crossref","unstructured":"Grasselli, G. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323, 1574\u20131581 (2020).","DOI":"10.1001\/jama.2020.5394"},{"key":"24156_CR61","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/infdis\/jiv246","volume":"212","author":"Z Cheng","year":"2015","unstructured":"Cheng, Z. et al. Identification of TMPRSS2 as a susceptibility gene for severe 2009 pandemic A(H1N1) influenza and A(H7N9) influenza. J. Infect. Dis. 212, 1214\u20131221 (2015).","journal-title":"J. Infect. Dis."},{"key":"24156_CR62","doi-asserted-by":"publisher","first-page":"e131834","DOI":"10.1172\/jci.insight.131834","volume":"5","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1. JCI Insight 5, e131834 (2020).","journal-title":"JCI Insight"},{"key":"24156_CR63","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100\u20132122 (2014).","journal-title":"Nat. Protoc."},{"key":"24156_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-012-1963-2","volume":"71","author":"J Nemunaitis","year":"2013","unstructured":"Nemunaitis, J. et al. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother. Pharm. 71, 35\u201341 (2013).","journal-title":"Cancer Chemother. Pharm."},{"key":"24156_CR65","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.ejca.2005.12.027","volume":"42","author":"MJ de Jonge","year":"2006","unstructured":"de Jonge, M. J. et al. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur. J. Cancer 42, 1768\u20131774 (2006).","journal-title":"Eur. J. Cancer"},{"key":"24156_CR66","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/DDDT.S68574","volume":"8","author":"J Lee","year":"2014","unstructured":"Lee, J. et al. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Des. Dev. Ther. 8, 1781\u20131788 (2014).","journal-title":"Drug Des. Dev. Ther."},{"key":"24156_CR67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","volume":"72","author":"Y Ishida","year":"2016","unstructured":"Ishida, Y. et al. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Eur. J. Clin. Pharm. 72, 185\u2013193 (2016).","journal-title":"Eur. J. Clin. Pharm."},{"key":"24156_CR68","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/jcph.730","volume":"56","author":"SK Agarwal","year":"2016","unstructured":"Agarwal, S. K., Hu, B., Chien, D., Wong, S. L. & Salem, A. H. Evaluation of Rifampin\u2019s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of Venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study. J. Clin. Pharm. 56, 1335\u20131343 (2016).","journal-title":"J. Clin. Pharm."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24156-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24156-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24156-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T01:06:44Z","timestamp":1675472804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24156-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["24156"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-24156-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-48659\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3907"}}